(Q33951340)

30 July 2017

1 reference

title

Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor (English)

1 reference

30 July 2017

Fung HB

1

1 reference

PubMed ID

10868554

30 July 2017

Kirschenbaum HL

series ordinal

2

1 reference

PubMed ID

10868554

30 July 2017

Hameed R

series ordinal

3

1 reference

30 July 2017

1 May 2000

1 reference

30 July 2017

Clinical Therapeutics

1 reference

30 July 2017

22

1 reference

30 July 2017

5

1 reference

30 July 2017

549-572

1 reference

Resistance to human immunodeficiency virus type 1 protease inhibitors.

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

New strategies to combat HIV drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogues.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

In vitro selection and characterization of VX-478 resistant HIV-1 variants.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

1 reference

7 January 2021

Longer-term immunologic effects and side effects of successful antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980044-2

7 January 2021

10.1016/S0149-2918(00)80044-2

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10868554